Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li AX, Wu X, Ye W, Chen S, Zhou W, Yu Y, Wang YZ, Ren X, Li H, Scherle P, Kuroki Y, Wang SE*. Cancer Res. 2012 Apr 3. [Epub ahead of print] CCL2 mediates crosstalk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.
Chandra M, Zang S, Li H, Zimmerman LJ, Champer J, Tsuyada A, Chow A, Zhou W, Yu Y, Gao H, Ren X, Lin RJ, Wang SE*. Mol Cell Biol. 2012 Apr 2. [Epub ahead of print] Nuclear translocation of type I TGF-β receptor confers a novel function in RNA processing.
Wu X, Somlo G, Yu Y, Palomares MR, Li XA, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang SE*. J Transl Med. 2012 Mar;10(1):42. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.
Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK, Wang SE*. Oncogene. 2011 Mar;30(12):1470-80. Transforming growth factor β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. PMCID: PMC3063856.
Chow A, Arteaga CL, Wang SE*. J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):81-8. When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.
Wang SE. J Signal Transduct. 2011 Feb;2011:804236. The functional crosstalk between HER2 tyrosine kinase and TGF-β signaling in breast cancer malignancy.
Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ, Wang SE*. Mol Cancer Res. 2010 Dec;8(12):1633-42. Context-dependent bidirectional regulation of the mutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells. PMCID: PMC3059495.
Rossi J, Wang E. European Pharmaceutical Review. 2010;1:54-7. Cancer-secreted microRNAs: travelers, messengers, and blood-borne biomarkers.
Wang SE*, Yu Y, Criswell TL, DeBusk LM, Lin PC, Zent R, Johnson DH, Ren X, Arteaga CL*. Oncogene. 2010 Jun;29(23):3335-48. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. PMCID: PMC2883631.
Wang SE*, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL*. Cancer Res. 2009 Jan;69(2):475-82. TGF-β induces clustering of HER2 and integrins by activating Src-FAK and receptor association to the cytoskeleton. PMCID: PMC2629389.
Wang SE, Hinow P, Bryce N, Weaver AM, Estrada L, Arteaga CL, Webb GF. Comput Math Meth Med. 2009 Mar;10(1):71-83. A mathematical model quantifies proliferation and motility effects of TGF-β on cancer cells.
Wang SE*, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL*. Mol Cell Biol. 2008 Sep;28(18):5605-20. TGF-β engages TACE and ErbB3 to activate PI3K/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. PMCID: PMC2546920.
Wang SE, Narasanna A, Whitwell CW, Wu FY, Friedman DB, Arteaga CL. J Biol Chem. 2007 Feb;282(8):5661-9. Convergence of p53 and TGF-β signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Dugger TC, Wu FY, Yang S, Gazdar AF, Muthuswamy SK, Arteaga CL. Cancer Cell. 2006 Jul;10(1):25-38. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGF receptors and resistance to EGFR tyrosine kinase inhibitors.
Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. Cancer Res. 2006 Oct;66(19):9591-600. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by TGF-β.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 04/12
